ArticleClinical cancer research : an official journal of the American Association for Cancer Research2012

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Fiona Simpkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.